SCHEMBL17295250

SCHEMBL17295250

CC(C)(C)c1ccc(CN=C2SC(=Cc3ccc4[nH]cnc4c3)C(=O)N2c2ccccc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 16/20 0.45
▸ S1PR3 Q99500 16/20 0.45
▸ ALDH1A1 P00352 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ HPGD P15428 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17295248 1.00 S1PR1 (0.45) S1PR1S1PR3ALDH1A1MAPTHPGD
SCHEMBL17295641 0.92 S1PR1 (0.48) S1PR1S1PR3ALDH1A1MAPTHPGD
SCHEMBL17295639 0.92 S1PR1 (0.48) S1PR1S1PR3ALDH1A1MAPTHPGD
SCHEMBL17295529 0.89 S1PR1 (0.45) S1PR1S1PR3ALDH1A1MAPTHPGD
SCHEMBL17295527 0.89 S1PR1 (0.45) S1PR1S1PR3ALDH1A1MAPTHPGD
SCHEMBL17295426 0.86 FAAH (0.44) S1PR1S1PR3ALDH1A1MAPTHPGD
SCHEMBL17295428 0.86 FAAH (0.44) S1PR1S1PR3ALDH1A1MAPTHPGD
SCHEMBL17295290 0.85 S1PR1 (0.50) S1PR1S1PR3ALDH1A1MAPTHPGD
SCHEMBL17295292 0.85 S1PR1 (0.50) S1PR1S1PR3ALDH1A1MAPTHPGD
SCHEMBL17295520 0.84 ALDH1A1 (0.49) S1PR1S1PR3ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3148990-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION Universität Bern (CH) 2017-04-05 — — EP disclosed
WO-2015181337-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION Universität Bern (CH) 2015-12-03 — — WO disclosed
Send feedback